Overview

Acthar SLE (Systemic Lupus Erythematosus)

Status:
Withdrawn

Trial end date:
2019-05-22

Target enrollment:

Participant gender:

Summary

This is a randomized study exploring the efficacy, safety and steroid sparing ability of two doses (40 U and 80 U) of Acthar in SLE patients with immune mediated hematologic manifestations requiring steroid use for a minimum of 2 weeks prior to screening.

Phase:

Phase 4

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborator:

Mallinckrodt

Treatments:

Adrenocorticotropic Hormone